SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

28 Jan 2025 Evaluate
The revenue for the December 2024 quarter is pegged at Rs. 1795.94 millions, about 11.32% up against Rs. 1613.35 millions recorded during the year-ago period.Profit for the quarter ended December 2024 grew by 1.60% to Rs. 210.51 millions from Rs. 207.19 millions.Operating Profit saw a handsome growth to 373.94 millions from 365.56 millions in the quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 1795.94 1613.35 11.32 5112.03 4416.42 15.75 6054.60 5983.40 1.19
Other Income 116.61 78.97 47.66 268.56 250.38 7.26 335.01 507.66 -34.01
PBIDT 373.94 365.56 2.29 1047.11 1070.56 -2.19 1406.68 1409.21 -0.18
Interest 6.68 17.88 -62.64 52.84 42.75 23.60 58.06 100.56 -42.26
PBDT 367.26 347.68 5.63 994.27 1027.81 -3.26 937.76 1308.65 -28.34
Depreciation 69.57 62.48 11.35 196.13 172.90 13.44 235.19 151.73 55.01
PBT 297.69 285.20 4.38 798.14 854.91 -6.64 702.57 1156.92 -39.27
TAX 87.18 78.01 11.75 222.98 233.85 -4.65 196.13 302.14 -35.09
Deferred Tax -15.53 13.84 -212.21 -37.45 22.13 -269.23 -75.49 -42.10 79.31
PAT 210.51 207.19 1.60 575.16 621.06 -7.39 506.44 854.78 -40.75
Equity 105.37 104.69 0.65 105.37 104.69 0.65 104.69 104.15 0.52
PBIDTM(%) 20.82 22.66 -8.11 20.48 24.24 -15.50 23.23 23.55 -1.35

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×